HitGen Inc. A (688222)
Shanghai Stock Exchange · China · prices in CNY · close of 23 Oct 2026
Key indicators
| Last close | CNY 37.08 |
|---|---|
| 52-week range | 21.46 – 47.58 |
| Return, 1 month / 3 months | −19.4% / +31.0% |
| Return, 1 year / 3 years | +63.4% / +173.7% |
| Trend | Uptrend |
| RSI (14) | 48 |
| Volatility (1 year) | 65.0% |
| Worst drawdown (1 year) | -43.1% |
| Average daily value traded | 798.40M CNY |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
HitGen Inc. is a drug-discovery company based in Chengdu, China, that builds and screens DNA-encoded libraries to identify small molecules that bind to biological targets. It offers these library screening services, along with related medicinal chemistry and discovery support, to pharmaceutical and biotechnology companies researching new medicines. Its customers use the company's platform to search very large collections of chemical compounds quickly during early-stage drug discovery.
HitGen Inc. A trades under the code 688222 on the Shanghai Stock Exchange in China, with its price quoted in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
HitGen Inc. A (688222) trades on the Shanghai Stock Exchange in China. It last closed at CNY 37.08 on 23 October 2026.
Its price-based Market X-Ray is 72 out of 100 (a strong price profile), ranking 238 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 63.4% and over the last three months it rose 31.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 94 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.4% | ||
| From 52-week high | -19.4% | ||
| Momentum | 96 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 31.0% | ||
| 6-month return | 39.0% | ||
| 12-month return, skipping the last month | 102.8% | ||
| Stability (higher is calmer) | 34 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 65.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -43.1% | ||
| Liquidity | 90 · Strong | Trades actively. | |
| Average daily value traded | 798.40M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | 26 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.1% |
|---|---|
| 1 month | −19.4% |
| 3 months | +31.0% |
| 6 months | +39.0% |
| 1 year | +63.4% |
| 3 years | +173.7% |
| 5 years | +46.0% |
Signals
| 50-day / 200-day average | 36.86 / 30.80 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.06 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Jun 2026 | CNY 0.1300 |
| 18 Jun 2025 | CNY 0.0600 |
| 21 Jun 2024 | CNY 0.0500 |
| 11 Jul 2022 | CNY 0.0500 |
| 13 Jul 2021 | CNY 0.0500 |
| 7 Jul 2020 | CNY 0.1250 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.